Deutsche Bank
EGRX

Deutsche Bank’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Deutsche Bank’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-48,800
Closed -$182K – 3755
2024
Q3 		$182K Hold
48,800
– – ﹤0.01% 2972
2024
Q2 		$273K Hold
48,800
– – ﹤0.01% 2641
2024
Q1 		$256K Hold
48,800
– – ﹤0.01% 2697
2023
Q4 		$255K Buy
48,800
+43,097
+756% +$425K ﹤0.01% 2741
2023
Q3 		$89.9K Sell
5,703
-48,836
-90% -$877K ﹤0.01% 3208
2023
Q2 		$1.06M Buy
54,539
+47,855
+716% +$1.14M ﹤0.01% 1954
2023
Q1 		$190K Buy
6,684
+1,911
+40% +$56.7K ﹤0.01% 3033
2022
Q4 		$140K Buy
4,773
+89
+2% +$2.83K ﹤0.01% 3163
2022
Q3 		$123K Sell
4,684
-689
-13% -$25.3K ﹤0.01% 3216
2022
Q2 		$239K Sell
5,373
-1,247
-19% -$57.3K ﹤0.01% 3071
2022
Q1 		$328K Sell
6,620
-740
-10% -$35.5K ﹤0.01% 2998
2021
Q4 		$375K Buy
7,360
+428
+6% +$22.2K ﹤0.01% 3010
2021
Q3 		$387K Sell
6,932
-2,684
-28% -$132K ﹤0.01% 3198
2021
Q2 		$412K Buy
9,616
+756
+9% +$31.2K ﹤0.01% 3344
2021
Q1 		$370K Sell
8,860
-628
-7% -$29.2K ﹤0.01% 3293
2020
Q4 		$442K Buy
9,488
+1,333
+16% +$62.3K ﹤0.01% 2993
2020
Q3 		$347K Sell
8,155
-62
-0.8% -$2.71K ﹤0.01% 2867
2020
Q2 		$394K Sell
8,217
-2,476
-23% -$124K ﹤0.01% 2778
2020
Q1 		$492K Sell
10,693
-7,352
-41% -$369K ﹤0.01% 2493
2019
Q4 		$1.08M Buy
18,045
+1,314
+8% +$78.4K ﹤0.01% 2324
2019
Q3 		$945K Buy
16,731
+1,510
+10% +$84.9K ﹤0.01% 2340
2019
Q2 		$845K Buy
15,221
+2,823
+23% +$147K ﹤0.01% 2951
2019
Q1 		$624K Sell
12,398
-2,603
-17% -$116K ﹤0.01% 3314
2018
Q4 		$602K Sell
15,001
-56,099
-79% -$2.89M ﹤0.01% 3209
2018
Q3 		$4.93M Buy
71,100
+31,631
+80% +$2.4M ﹤0.01% 2206
2018
Q2 		$2.99M Sell
39,469
-28,787
-42% -$1.81M ﹤0.01% 2681
2018
Q1 		$3.6M Buy
68,256
+47,440
+228% +$2.76M ﹤0.01% 2473
2017
Q4 		$1.11M Sell
20,816
-88,984
-81% -$4.95M ﹤0.01% 3132
2017
Q3 		$6.55M Buy
109,800
+24,693
+29% +$1.49M ﹤0.01% 1735
2017
Q2 		$6.71M Buy
85,107
+64,058
+304% +$5.24M ﹤0.01% 1708
2017
Q1 		$1.74M Sell
21,049
-3,960
-16% -$294K ﹤0.01% 2331
2016
Q4 		$1.98M Sell
25,009
-52,492
-68% -$3.81M ﹤0.01% 2267
2016
Q3 		$5.42M Buy
77,501
+10,000
+15% +$554K ﹤0.01% 1674
2016
Q2 		$2.62M Buy
67,501
+44,361
+192% +$1.85M ﹤0.01% 2207
2016
Q1 		$936K Sell
23,140
-3,495
-13% -$222K ﹤0.01% 2854
2015
Q4 		$2.36M Sell
26,635
-15,892
-37% -$1.25M ﹤0.01% 2326
2015
Q3 		$3.15M Buy
42,527
+22,043
+108% +$1.83M ﹤0.01% 2147
2015
Q2 		$1.66M Buy
+20,484
New +$1.33M ﹤0.01% 2612
2015
Q1 		– Sell
-1,200
Closed -$18K – 6095
2014
Q4 		$18K Buy
+1,200
New +$15.3K ﹤0.01% 5541
2014
Q3 		– Sell
-9,985
Closed -$142K – 6124
2014
Q2 		$142K Buy
9,985
+9,176
+1,134% +$105K ﹤0.01% 4359
2014
Q1 		$9K Buy
+809
New +$11K ﹤0.01% 5065

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Deutsche Bank's EGRX Position: Q4 2024 in Review

Deutsche Bank sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 48,800 shares — an estimated $182K sold.

Deutsche Bank first reported a position in EGRX in Q1 2014 and held it in 41 quarters. The position peaked at $6.71M in Q2 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Deutsche Bank reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Deutsche Bank sold 48,800 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $182K.
  • Deutsche Bank first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 41 quarters.
  • Deutsche Bank's Eagle Pharmaceuticals, Inc. position peaked at $6.71M in Q2 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Deutsche Bank's 13F filing for Q4 2024, filed 14 Feb 2025.